RYTM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rhythm Pharmaceuticals Inc (RYTM) does not present a compelling buy opportunity for a beginner, long-term investor at this time. While the company has shown some positive financial growth and received favorable analyst ratings, the lack of strong proprietary trading signals, hedge fund selling trends, recent governance changes, and short-term bearish stock trends suggest a cautious approach. Holding off for clearer positive catalysts or a more favorable entry point is recommended.
The MACD is positive and expanding, indicating bullish momentum, but RSI is neutral at 52.628, showing no clear overbought or oversold conditions. Moving averages are converging, suggesting indecision in the market. Key support is at 76.926, and resistance is at 89.376, with the current pre-market price near resistance levels, limiting immediate upside potential.
FDA approval for Imcivree to treat acquired hypothalamic obesity, which expands the drug's commercial potential. Analysts have raised price targets and maintain Buy/Outperform ratings, reflecting optimism about the company's growth potential.
Hedge funds are selling heavily, with a 288.14% increase in selling activity over the last quarter. Recent board changes have introduced uncertainty, as reflected in short-term stock volatility. The stock has a 70% chance of declining in the short term based on candlestick pattern analysis.
In Q4 2025, revenue increased by 36.87% YoY to $57.25M, and net income improved by 9.42% YoY to -$48.84M. EPS also improved slightly to -0.73. Gross margin increased to 91.61%, indicating strong operational efficiency despite ongoing losses.
Analysts remain optimistic, with multiple firms raising price targets (e.g., RBC to $136, BofA to $149, and Citizens to $155) and maintaining Buy/Outperform ratings. However, some analysts have recently lowered price targets due to the Phase 3 EMANATE trial miss, reflecting mixed sentiment.
